Enovis Corporation (NYSE:ENOV) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. raised its holdings in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 734.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 275,058 shares of the company's stock after acquiring an additional 242,096 shares during the quarter. Victory Capital Management Inc. owned approximately 0.48% of Enovis worth $10,510,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in ENOV. HighTower Advisors LLC acquired a new position in Enovis in the fourth quarter valued at $275,000. Commonwealth Equity Services LLC acquired a new position in Enovis in the fourth quarter valued at approximately $402,000. Natixis Advisors LLC boosted its position in shares of Enovis by 52.8% during the fourth quarter. Natixis Advisors LLC now owns 19,381 shares of the company's stock worth $850,000 after buying an additional 6,701 shares during the period. Xponance Inc. increased its holdings in shares of Enovis by 7.8% in the fourth quarter. Xponance Inc. now owns 6,380 shares of the company's stock valued at $280,000 after buying an additional 462 shares in the last quarter. Finally, Sei Investments Co. grew its position in Enovis by 51.0% during the 4th quarter. Sei Investments Co. now owns 453,241 shares of the company's stock worth $19,888,000 after purchasing an additional 153,006 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Trading Up 1.4%

Shares of ENOV traded up $0.37 during mid-day trading on Friday, reaching $27.53. The company's stock had a trading volume of 1,126,050 shares, compared to its average volume of 1,855,950. The company has a current ratio of 2.55, a quick ratio of 1.32 and a debt-to-equity ratio of 0.52. Enovis Corporation has a 52 week low of $25.93 and a 52 week high of $49.83. The company's fifty day moving average price is $31.86 and its two-hundred day moving average price is $36.73. The stock has a market cap of $1.57 billion, a PE ratio of -1.97 and a beta of 1.70.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. The company had revenue of $558.83 million for the quarter, compared to analysts' expectations of $558.80 million. During the same quarter in the previous year, the business posted $0.50 EPS. Enovis's revenue was up 8.2% compared to the same quarter last year. On average, analysts predict that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Needham & Company LLC dropped their price objective on shares of Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a report on Friday, May 9th. Evercore ISI lowered their target price on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. JMP Securities dropped their price objective on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Finally, Canaccord Genuity Group decreased their price objective on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $55.60.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.